Skip to main content

Table 1 Selected monoclonal antibodies in ALL and AML

From: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Selected monoclonal antibodies in ALL Selected monoclonal antibodies in AML  
Rituximab anti-CD20 antibody SGN-CD33A anti-CD33 pyrrolobenzodiazepine dimer
Ofatumumab anti-CD20 antibody AMG 330 anti-CD33 and CD3, bi-specific T cell engager antibody
Epratuzumab anti-CD22 antibody MGD006 anti-CD123 and CD3, dual affinity retargeting molecule
Alemtuzumab anti-CD52 antibody CSL362 anti-CD123 antibody
Inotuzumab ozogamicin Monoclonal anti-CD22 immunotoxin SL-401 diphtheria toxin interleukin-3 fusion protein against CD123
Blinatumomab bi-specific T cell engager antibody   
Moxetunomab pasudotox conjugated immunotoxin targeting CD22